Inclusion Criteria: All of the following inclusion criteria must be met for a subject to be enrolled in this clinical trial.
* Male or female subjects aged between 19 and 75 years, inclusive, as of the date of written informed consent.
* Voluntarily decided to participate in the study and signed the informed consent form in writing
* Subjects who desire improvement in nasolabial folds and have a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4.
* Subjects whose bilateral nasolabial folds appear visually symmetrical, although WSRS scores do not need to be identical on both sides.
* Subjects who agree to use appropriate contraception from the date of signing the informed consent form until 3 months after the end of the clinical trial. \*Examples of acceptable contraception include: copper intrauterine device (IUD), hormone-releasing IUD, condoms, vasectomy, tubal ligation, spermicides, vaginal contraceptive film, subdermal implants, injectable contraceptives, female condoms, and oral contraceptives.
* Subjects who agree not to undergo any procedures or treatments that may affect the nasolabial folds during the study period.
* Subjects who are able to understand and comply with the study instructions and are available for the entire duration of the study.
Exclusion Criteria: Subjects who meet any of the following exclusion criteria will not be eligible for participation in this clinical trial.
* Received antithrombotic agents (except for low-dose aspirin \[100 mg, up to 300 mg/day\]) or nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to screening
* Used topical agents on the device application area within 4 weeks prior to screening or plans to use them during the study period, including corticosteroids, retinoids, alpha hydroxy acids, skin-whitening agents, or anti-wrinkle functional cosmetics. (- Topical corticosteroids for therapeutic purposes may be used for a short duration of up to 14 consecutive days.)
* Received invasive laser treatment, deep peeling procedures, or filler injections on the device application area within 24 weeks prior to screening.
* Received any wrinkle improvement procedures on the device application area within 24 weeks prior to screening, including:
* Botulinum toxin injections
* Soft-tissue augmentation
* Facial lifting surgery
* Dermabrasion
* Dermal photo-rejuvenation
* Received any wrinkle improvement procedures on the device application area within 1 year prior to screening, including facial augmentation using calcium hydroxylapatite or wrinkle treatment using approved fillers.
* Received an injection of calcium hydroxylapatite in the nasolabial fold area within 1 year prior to screening.
* Has permanent dermal implants such as Softform or silicone in the nasolabial fold area.
* Underwent facial lifting involving thread-based tissue fixation (e.g., thread lifting) that affected the nasolabial fold area within 1 year prior to screening
* Has taken medications that may affect skin hypersensitivity testing, including:
① First- or second-generation antihistamines (e.g., chlorpheniramine, hydroxyzine, cetirizine, fexofenadine, loratadine) within 7 days prior to screening
② Tricyclic antidepressants (e.g., imipramine, doxepin) within 11 days prior to screening
③ H2-receptor antagonists (e.g., ranitidine) within 1 day prior to screening
* Has scars, skin disorders, wounds, infections, inflammation, or other skin lesions in the nasolabial fold area that may affect the outcome of this clinical trial.
* Has a history of anaphylaxis or severe systemic allergic reactions.
* Has a history of hypertrophic scarring, keloid formation, or hyperpigmentation.
* Has a known hypersensitivity to Hyaluronic acid (HA).
* Has experienced adverse reactions to EMLA Cream or other lidocaine-based anesthetic products.
* Has or has had autoimmune diseases including AIDS, or is immunocompromised.
* Has clinically significant disorders of the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems, or has psychiatric conditions that may affect participation in this clinical trial.
* Tested positive on the skin hypersensitivity test indicating hypersensitivity to the investigational device or control device at the time of screening.
* Participated in other clinical trial(s) within 30 days prior to screening
* Pregnant or breast-feeding women (women of childbearing potential must undergo a pregnancy test)
* Subjects who, due to physical, neurological, or psychological conditions, are unable to comply with all aspects of the screening, evaluation, treatment, and follow-up schedule.
* Subjects who are otherwise unable to communicate or follow instructions properly.
* Determined by the principal investigator to be unable to participate in the study for other reasons
